# MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

> **NCT02989064** · PHASE1 · COMPLETED · sponsor: **Adaptimmune** · enrollment: 10 (actual)

## Conditions studied

- Urothelial Carcinoma
- Head and Neck Cancer
- Melanoma
- Bladder Urothelial Carcinoma

## Interventions

- **GENETIC:** Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells

## Key facts

- **NCT ID:** NCT02989064
- **Lead sponsor:** Adaptimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2019-12-18
- **Final completion:** 2020-06-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02989064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02989064, "MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02989064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*